Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast Cancer

Video

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer.

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer (TNBC).

Adjuvant chemotherapy has proven to be effective for patients with TNBC, but Yee argues it is better to more effective in the neoadjuvant setting. There are very few patients, if any, who are at a low-enough risk to not require any therapy. The nature of the disease, Yee says, means there is nothing to target when it comes to treatment. Conventional chemotherapy remains the only viable option, and most, if not all, patients require therapy.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "